Novo Nordisk A/S Stock Forecast for 2022 - 2025 - 2030

Updated on 05/27/2022

Stock Rating
5 / 10
Price Target
kr820.00
Consensus
Hold
Upside
25.19%
Analysts
11
Stock Rating
0
Upside
25.19%
Analysts
11
Price Target
kr820.00

If the average price target of kr820.00 set by eleven distinguished experts for Novo Nordisk A/S over the past few weeks is reached this year, there would be a potential upside of approximately 25.19% from the last closing price in February, 2022. This potential increase is based on a high estimate of kr1005.00 and a low estimate of kr540.00. If you're thinking of investing in NOVO B stock, it's critical to check out its competitors as well.

kr820.00

25.19% Upside

Hold
Hold

Novo Nordisk A/S Fair Value Forecast for 2022 - 2025 - 2030

In the past three years, Novo Nordisk A/S's Fair Value has seen a relatively significant increase, rising from kr366.55 to kr477.23. This represents a growth of 30.19%. Analysts predict that Novo Nordisk A/S's Fair Value will increase slightly in the upcoming year, reaching kr516.93. This would represent an increase of 8.32%. Over the next nine years, experts predict that Novo Nordisk A/S's Fair Value will grow at a rate of 108.77%

2022 Fair Value Forecast
kr516.93
2023 Fair Value Forecast
kr568.44
2024 Fair Value Forecast
kr625.09
2025 Fair Value Forecast
kr678.85
2026 Fair Value Forecast
kr737.77
2027 Fair Value Forecast
kr799.18
2028 Fair Value Forecast
kr862.02
2029 Fair Value Forecast
kr928.00
2030 Fair Value Forecast
kr996.30
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
JNJ Stock Forecast Johnson & Johnson Outperform 12
$181.09 $187.12 2.71% 16
PFE Stock Forecast Pfizer Outperform 3
$53.91 $58.26 2.02% 16
AZN Stock Forecast AstraZeneca PLC Outperform 18
£105.80 £136.08 37.87% 13
ABT Stock Forecast Abbott Laboratories Outperform 14
$116.69 $141.24 19.98% 19
NOVN Stock Forecast Novartis Outperform 0
CHF77.22 CHF103.75 19.24% 12

Novo Nordisk A/S Revenue Forecast for 2022 - 2025 - 2030

In the past three years, Novo Nordisk A/S's Revenue has seen a relatively significant increase, rising from kr111.83B to kr140.80B. This represents a growth of 25.9%. Analysts predict that Novo Nordisk A/S's Revenue will increase slightly in the upcoming year, reaching kr151.16B. This would represent an increase of 7.36%. Over the next nine years, experts predict that Novo Nordisk A/S's Revenue will grow at a rate of 79.16%

2022 Rev Forecast
kr151.16B
2023 Rev Forecast
kr161.52B
2024 Rev Forecast
kr173.97B
2025 Rev Forecast
kr185.81B
2026 Rev Forecast
kr198.16B
2027 Rev Forecast
kr211.20B
2028 Rev Forecast
kr224.42B
2029 Rev Forecast
kr238.11B
2030 Rev Forecast
kr252.26B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
SAN Stock Forecast Sanofi Outperform 18
103.72€ 104.66€ 10.13% 20
MDT Stock Forecast Medtronic Outperform 18
$99.08 $123.50 16.07% 5
CSL Stock Forecast CSL Outperform 0
$266.28 $228.01 -14.01% 10

Novo Nordisk A/S Dividend per Share Forecast for 2022 - 2025 - 2030

Novo Nordisk A/S's DPS has seen considerable growth in the last three years, going from kr8.15 to kr10.40 – a gain of 27.61% In the next year, analysts believe that DPS will reach an unimpressive kr11.20 – an increase of 7.71% For the next nine years, the forecast is for DPS to grow by 100.35%

2022 DPS Forecast
kr11.20
2023 DPS Forecast
kr12.24
2024 DPS Forecast
kr13.39
2025 DPS Forecast
kr14.48
2026 DPS Forecast
kr15.66
2027 DPS Forecast
kr16.90
2028 DPS Forecast
kr18.15
2029 DPS Forecast
kr19.47
2030 DPS Forecast
kr20.84
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
GILD Stock Forecast Gilead Sciences Outperform 11
$64.80 $75.96 6.48% 19
SHW Stock Forecast Sherwin Williams Outperform 15
$276.35 $302.15 9.1% 22
BAYN Stock Forecast Bayer Outperform 16
66.58€ 67.79€ 14.15% 14

Novo Nordisk A/S Free Cash Flow Forecast for 2022 - 2025 - 2030

Novo Nordisk A/S's Free Cash Flow has seen major growth over the last three years, jumping from kr35.09B to kr48.67B – an increase of 38.68%. In the next year, analysts predict that Free Cash Flow will reach a reasonable kr53.68B – an increase of 10.3%. For the next nine years, the forecast is for Free Cash Flow to grow by 122.37%

2022 FCF Forecast
kr53.68B
2023 FCF Forecast
kr59.58B
2024 FCF Forecast
kr65.70B
2025 FCF Forecast
kr71.96B
2026 FCF Forecast
kr78.65B
2027 FCF Forecast
kr85.60B
2028 FCF Forecast
kr92.83B
2029 FCF Forecast
kr100.38B
2030 FCF Forecast
kr108.22B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BSX Stock Forecast Boston Scientific Outperform 15
$41.20 $49.85 21.36% 23
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥2.83k ¥0.00 41.37% 0
BAX Stock Forecast Baxter International Outperform 17
$76.16 $89.29 18.17% 3

Novo Nordisk A/S Net Income Forecast for 2022 - 2025 - 2030

In three years, Net Income for Novo Nordisk A/S has grown by a respectable 23.63%, going from kr38.63B to kr47.76B. In the coming year, analysts are expecting a small increase in Net Income, predicting it will reach kr50.97B – an increase of 6.72%. Over the next nine years, experts anticipate that Net Income growth for Novo Nordisk A/S will be 89.58%.

2022 NI Forecast
kr50.97B
2023 NI Forecast
kr55.32B
2024 NI Forecast
kr60.10B
2025 NI Forecast
kr64.54B
2026 NI Forecast
kr69.42B
2027 NI Forecast
kr74.48B
2028 NI Forecast
kr79.62B
2029 NI Forecast
kr85.00B
2030 NI Forecast
kr90.54B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
PPG Stock Forecast PPG Industries Outperform 13
$130.03 $156.50 21.89% 20
BIIB Stock Forecast Biogen Outperform 11
$206.20 $287.21 10.33% 24
HZNP Stock Forecast Horizon Therapeutics Public Buy 0
$86.60 $0.00 61.66% 8

Novo Nordisk A/S EBITDA Forecast for 2022 - 2025 - 2030

Over the last three years, Novo Nordisk A/S's EBITDA has increased by 24.41%, going from kr51.08B to kr63.55B. In the next year, analysts are expecting a small increase in EPS, predicting it will reach kr67.98B – an increase of 6.97%. The 2030 forecast is for EBITDA to reach kr105.79B or grow by 66.46%.

2022 EBITDA Forecast
kr67.98B
2023 EBITDA Forecast
kr71.82B
2024 EBITDA Forecast
kr76.46B
2025 EBITDA Forecast
kr81.03B
2026 EBITDA Forecast
kr85.64B
2027 EBITDA Forecast
kr90.52B
2028 EBITDA Forecast
kr95.47B
2029 EBITDA Forecast
kr100.55B
2030 EBITDA Forecast
kr105.79B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
ALNY Stock Forecast Alnylam Pharmaceuticals Outperform 7
$127.77 $209.00 60.05% 10
GRF Stock Forecast Grifols Outperform 0
16.07€ 27.25€ 31.92% 6
IPN Stock Forecast Ipsen Hold 17
96.45€ 94.86€ 5.75% 9

Novo Nordisk A/S EBIT Forecast for 2022 - 2025 - 2030

In the past three years, Novo Nordisk A/S's EBIT has seen a tremendous growth rate, increasing from kr47.28B to kr59.34B – an increase of 25.52%. For next year, the 0 analysts predict earnings per share of kr63.62B, which would mean an increase of 7.21%. Over the next nine years, the pros' prediction is EBIT of kr99.92B, which would mean a 9-year growth forecast of 68.38%.

2022 EBIT Forecast
kr63.62B
2023 EBIT Forecast
kr67.18B
2024 EBIT Forecast
kr71.71B
2025 EBIT Forecast
kr76.10B
2026 EBIT Forecast
kr80.51B
2027 EBIT Forecast
kr85.22B
2028 EBIT Forecast
kr89.98B
2029 EBIT Forecast
kr94.87B
2030 EBIT Forecast
kr99.92B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
500124 Stock Forecast Dr. Reddy's Laboratories Outperform 0
Rp4.32k Rp5.47k 14.56% 12
SOBI Stock Forecast Swedish Orphan Biovitrum AB (p... Outperform 16
kr213.20 kr210.63 20.31% 6
ARNA Stock Forecast Arena Pharmaceuticals - 0
$99.99 $95.80 -100% 7

Novo Nordisk A/S EPS Price Prediction Forecast for 2022 - 2025 - 2030

In the past three years, Novo Nordisk A/S's EPS has seen a relatively significant increase, rising from kr15.93 to kr20.74. This represents a growth of 30.19%. Analysts predict that Novo Nordisk A/S's EPS will increase slightly in the upcoming year, reaching kr22.47. This would represent an increase of 8.32%. Over the next nine years, experts predict that Novo Nordisk A/S's EPS will grow at a rate of 108.77%

2022 EPS Forecast
kr22.47
2023 EPS Forecast
kr24.70
2024 EPS Forecast
kr27.17
2025 EPS Forecast
kr29.50
2026 EPS Forecast
kr32.06
2027 EPS Forecast
kr34.73
2028 EPS Forecast
kr37.46
2029 EPS Forecast
kr40.33
2030 EPS Forecast
kr43.30
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
PRGO Stock Forecast Perrigo Outperform 16
$40.33 $53.30 19.02% 1
APN Stock Forecast Aspen Pharmacare Holdings Outperform 0
R203.93 R193.00 20.38% 0
4403 Stock Forecast NOF Buy 0
¥5.81k ¥0.00 4.99% 0

© Copyright 2022 | Stock Forecast | All Rights Reserved